Long‐term remission of TP53‐mutated therapy‐related acute myeloid leukaemia following allogeneic stem cell transplantation in a heart transplant recipient: A case report and literature review

Documenti analoghi

• Clinical perspectives on post‐induction maintenance therapy in patients with acute myeloid leukaemia in remission who are ineligible for allogeneic haematopoietic stem cell transplantation
  di: Kendra Sweet, et al.
  Pubblicazione: (2024)
• The efficacy of targeted and immune‐based therapies in adults with TP53‐mutated acute lymphoblastic leukaemia
  di: Hoda Pourhassan, et al.
  Pubblicazione: (2025)
• Dynamics of measurable residual disease for risk stratification and guiding allogeneic transplant in acute myeloid leukaemia patients with myelodysplasia‐related mutations in first remission
  di: Ling Jiang, et al.
  Pubblicazione: (2024)
• Strategies to reduce relapse risk in patients undergoing allogeneic stem cell transplantation for acute myeloid leukaemia
  di: Francesca A. M. Kinsella, et al.
  Pubblicazione: (2024)
• Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed/refractory acute myeloid leukaemia: A subanalysis of the AVALON study
  di: Elisabetta Petracci, et al.
  Pubblicazione: (2025)